The Journal of rheumatology · 2019
Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Andersen Kathleen M, Cheah Jonathan T L, March Lyn, Bartlett Susan J, Beaton Dorcas, Bingham Clifton O, Brooks Peter M, Christensen Robin, Conaghan Philip G, D'Agostino Maria-Antonietta, de Wit Maarten, Dueck Amylou C, Goodman Susan M, Grosskleg Shawna, Hill Catherine L, Howell Martin, Mackie Sarah L, Richards Bethan, Shea Beverly, Singh Jasvinder A, Strand Vibeke, Tugwell Peter, Wells George A, Simon Lee S
Аннотация
OBJECTIVE: Outcome Measures in Rheumatology (OMERACT) convened a premeeting in 2018 to bring together patients, regulators, researchers, clinicians, and consumers to build upon previous OMERACT drug safety work, with patients fully engaged throughout all phases.
METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.
RESULTS: Five themes pertaining to drug safety measurement emerged.
CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.
METHODS: Day 1 included a brief introduction to the history of OMERACT and methodology, and an overview of current efforts within and outside OMERACT to identify patient-reported medication safety concerns. On Day 2, two working groups presented results; after each, breakout groups were assembled to discuss findings.
RESULTS: Five themes pertaining to drug safety measurement emerged.
CONCLUSION: Current approaches have failed to include data from the patient's perspective. A better understanding of how individuals with rheumatic diseases view potential benefits and harms of therapies is essential.